Assembly Biosciences, Inc. (NASDAQ:ASMB) Director Buys $49,983.22 in Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) Director Michael Houghton bought 3,202 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average price of $15.61 per share, with a total value of $49,983.22. Following the acquisition, the director now owns 3,202 shares of the company’s stock, valued at $49,983.22. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Assembly Biosciences Price Performance

ASMB stock traded down $0.25 during midday trading on Tuesday, hitting $15.78. The stock had a trading volume of 26,731 shares, compared to its average volume of 25,521. The business has a 50-day moving average of $16.04 and a two-hundred day moving average of $15.59. Assembly Biosciences, Inc. has a 52-week low of $9.12 and a 52-week high of $19.93.

Institutional Trading of Assembly Biosciences

Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its position in Assembly Biosciences by 5,137.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 3,442 shares during the period. Acadian Asset Management LLC increased its stake in shares of Assembly Biosciences by 131.0% during the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 7,690 shares in the last quarter. FMR LLC lifted its holdings in shares of Assembly Biosciences by 29.7% during the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 3,635 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Assembly Biosciences by 39.2% in the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after purchasing an additional 15,451 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in shares of Assembly Biosciences in the 2nd quarter worth approximately $6,421,000. Institutional investors own 19.92% of the company’s stock.

Analyst Upgrades and Downgrades

ASMB has been the subject of several research reports. Jefferies Financial Group upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $2.00 to $35.00 in a report on Friday, September 20th. HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a research note on Friday.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.